Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab

Annals of Thoracic Surgery

Volumn 92, Issue 4, 2011, Pages 1428-1434

  Lick, Scott D ^a   Beckles, Daniel L ^a   Piovesana, Giovanni ^a   Vaidya, Smita ^b   Indrikovs, Alexander ^a   Barbagelata, N Alexander ^a   Valentine, Vincent ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CYCLOSPORIN; EVEROLIMUS; FOLINIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; PREDNISONE; PYRIMETHAMINE SULFADIAZINE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEFT VENTRICULAR ASSIST DEVICE; LYMPHOCYTOTOXICITY; MALE; MEDICAL RECORD REVIEW; OPPORTUNISTIC INFECTION; PLASMAPHERESIS; PRIORITY JOURNAL; SURVIVAL TIME; TOXOPLASMOSIS;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CARDIOPULMONARY BYPASS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HISTOCOMPATIBILITY TESTING; HUMANS; INCIDENCE; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; PLASMAPHERESIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TEXAS; YOUNG ADULT;

EID: 80053338023     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2011.04.064     Document Type: Article

References (22)

1. P.M. Eckman, M. Hanna, D.O. Taylor, R.C. Starling, and G.V. Gonzalez-Stawinski Management of the sensitized adult heart transplant candidate Clin Transplant 24 2010 726 734
2. J. Kobashigawa, M. Mehra, and L. West Report from a consensus conference on the sensitized patient awaiting heart transplantation J Heart Lung Transplant 28 2009 213 225
3. P.C. Patel, C.I. Fitzsimmons, and P.A. Kaiser Treatment of HLA sensitized pre-transplant patients with mechanical support is effective for PRA reduction J Heart Lung Transplant 26 suppl 2007 S104 S105
4. M. Weston, M. Rolfe, T. Haddad, and M. Lopez-Cepero Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants Clin Transpl 2009 393 399
5. D.F. Larson, D.K. Elkund, F. Arabia, and J.G. Copeland Plasmapheresis during cardiopulmonary bypass: a proposed treatment for presensitized cardiac transplantation patients J Extra Corpor Technol 31 1999 177 183 (Pubitemid 30176832)
6. E.J. Wright, W.P. Fiser, and R.E. Edens Cardiac transplant outcomes in pediatric patients with pre-formed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch J Heart Lung Transplant 26 2007 1163 1169 (Pubitemid 350088510)
7. J.D. Smith, A.J. Danskine, R.M. Laylor, M.L. Rose, and M.H. Yacoub The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation Transpl Immunol 1 1993 60 65
8. M.H. Gilleece, and T.M. Dexter Effect of Campath-1H antibody on human hematopoietic progenitors in vitro Blood 82 1993 807 812 (Pubitemid 23221659)
9. G. Hale, M.Q. Xia, H.P. Tighe, M.J. Dyer, and H. Waldmann The CAMPATH-1 antigen (CDw52) Tissue Antigens 35 1990 118 127 (Pubitemid 20152978)
10. A. Agarwal, L.Y. Shen, and A.D. Kirk The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation Transpl Immunol 20 2008 6 11
11. P.J. Morris, and N.K. Russell Alemtuzumab (Campath-1H): a systematic review in organ transplantation Transplantation 81 2006 1361 1367 (Pubitemid 43847142)
12. K.J. Woodside, and S.D. Lick Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection J Heart Lung Transplant 26 2007 750 752 (Pubitemid 47001712)
13. S.D. Lick, S. Vaidya, A.C. Kollar, P.J. Boor, and R.A. Vertrees Peri-operative alemtuzumab (Campath-1H) and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular assist device support J Heart Lung Transplant 27 2008 1036 1039
14. D.D. Bloom, H. Hu, J.H. Fechner, and S.J. Knechtle T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients Transplantation 81 2006 81 87 (Pubitemid 43122153)
15. A. Keogh, M. Richardson, and P. Ruygrok Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial Circulation 110 2004 2694 2700 (Pubitemid 39453021)
16. P. Ruggenenti, N. Perico, and E. Gotti Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury Transplantation 84 2007 956 964 (Pubitemid 350287376)
17. M. Battaglia, A. Stabilini, and M.G. Roncarolo Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells Blood 105 2005 4743 4748
18. J.P. Pearl, J. Parris, and D.A. Hale Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion Am J Transplant 5 2005 465 474 (Pubitemid 40313337)
19. P. Trzonkowski, M. Zilvetti, P. Friend, and K.J. Wood Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression Transplantation 82 2006 1342 1351 (Pubitemid 44834311)
20. P. Trzonkowski, M. Zilvetti, and S. Chapman Homeostatic repopulation by CD28CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression Am J Transplant 8 2008 338 347
21. A. Zeevi, S. Husain, and K.J. Spichty Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab Am J Transplant 7 2007 471 475 (Pubitemid 46096343)
22. J.K. Kirklin, D.C. Naftel, and R.L. Kormos Third INTERMACS Annual Report: the evolution of destination therapy in the United States J Heart Lung Transplant 30 2011 115 123